BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Licht C, Schlötzer-schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN II – genetically determined by defective complement regulation? Pediatr Nephrol 2007;22:2-9. [DOI: 10.1007/s00467-006-0299-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Suzuki K, Tsugawa K, Oki E, Aita K, Endo M, Waga S, Ito E, Tanaka H. Dense deposit disease presenting as endocapillary proliferative nephritis. Pediatr Int 2009;51:739-41. [PMID: 19799741 DOI: 10.1111/j.1442-200X.2009.02901.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Heeringa SF, Cohen CD. Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come. Clin Dev Immunol. 2012;2012:695131. [PMID: 23227086 DOI: 10.1155/2012/695131] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
3 Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, Macher MA, Zuber J, Karras A, Provot F. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454-464. [PMID: 22456601 DOI: 10.1038/ki.2012.63] [Cited by in Crossref: 328] [Cited by in F6Publishing: 285] [Article Influence: 32.8] [Reference Citation Analysis]
4 Kirpalani A, Jawa N, Smoyer WE, Licht C; Midwest Pediatric Nephrology Consortium. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children. Kidney Int Rep 2020;5:2313-24. [PMID: 33305125 DOI: 10.1016/j.ekir.2020.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
5 García-de la Puente S, Orozco-loza IL, Zaltzman-girshevich S, de Leon Bojorge B. Prognostic factors in children with membranoproliferative glomerulonephritis type I. Pediatr Nephrol 2008;23:929-35. [DOI: 10.1007/s00467-008-0754-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
6 Servais A, Noël LH, Dragon-Durey MA, Gübler MC, Rémy P, Buob D, Cordonnier C, Makdassi R, Jaber W, Boulanger E. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum Pathol. 2011;42:1305-1311. [PMID: 21396679 DOI: 10.1016/j.humpath.2010.11.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
7 Hohenstein B, Amann K, Menne J. Membranoproliferative Glomerulonephritis und C3‑Glomerulopathie. Internist 2019;60:458-67. [DOI: 10.1007/s00108-019-0572-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Bataille S, Kaplanski G, Boucraut J, Halfon P, Camus C, Daniel L, Burtey S, Berland Y, Dussol B. Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits. Am J Nephrol. 2012;35:134-140. [PMID: 22248563 DOI: 10.1159/000335375] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sethi S, Gamez JD, Vrana JA, Theis JD, Bergen HR 3rd, Zipfel PF, Dogan A, Smith RJ. Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway. Kidney Int. 2009;75:952-960. [PMID: 19177158 DOI: 10.1038/ki.2008.657] [Cited by in Crossref: 136] [Cited by in F6Publishing: 114] [Article Influence: 10.5] [Reference Citation Analysis]
10 Büttner-Mainik A, Parsons J, Jérôme H, Hartmann A, Lamer S, Schaaf A, Schlosser A, Zipfel PF, Reski R, Decker EL. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol J 2011;9:373-83. [PMID: 20723134 DOI: 10.1111/j.1467-7652.2010.00552.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
11 Habbig S, Mihatsch MJ, Heinen S, Beck B, Emmel M, Skerka C, Kirschfink M, Hoppe B, Zipfel PF, Licht C. C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int. 2009;75:1230-1234. [PMID: 18633337 DOI: 10.1038/ki.2008.354] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
12 Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, Cornell LD, Krishnan SG, Smith RJ. Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis. 2010;56:977-982. [PMID: 20832153 DOI: 10.1053/j.ajkd.2010.06.021] [Cited by in Crossref: 89] [Cited by in F6Publishing: 76] [Article Influence: 7.4] [Reference Citation Analysis]
13 Spartà G, Gaspert A, Neuhaus TJ, Weitz M, Mohebbi N, Odermatt U, Zipfel PF, Bergmann C, Laube GF. Membranoproliferative glomerulonephritis and C3 glomerulopathy in children: change in treatment modality? A report of a case series. Clin Kidney J 2018;11:479-90. [PMID: 30094012 DOI: 10.1093/ckj/sfy006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Cho HY, Lee BS, Moon KC, Ha IS, Cheong HI, Choi Y. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007;22:874-80. [PMID: 17295030 DOI: 10.1007/s00467-007-0438-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
15 Vivarelli M, van de Kar N, Labbadia R, Diomedi-Camassei F, Thurman JM. A clinical approach to children with C3 glomerulopathy. Pediatr Nephrol 2021. [PMID: 34002292 DOI: 10.1007/s00467-021-05088-7] [Reference Citation Analysis]
16 Piscione TD, Licht C. Genetics of proteinuria: an overview of gene mutations associated with nonsyndromic proteinuric glomerulopathies. Adv Chronic Kidney Dis 2011;18:273-89. [PMID: 21782134 DOI: 10.1053/j.ackd.2011.06.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
17 Goodship TH, Pappworth IY, Toth T, Denton M, Houlberg K, McCormick F, Warland D, Moore I, Hunze EM, Staniforth SJ. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol Immunol. 2012;52:200-206. [PMID: 22721707 DOI: 10.1016/j.molimm.2012.05.009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
18 Meyers KE, Liapis H, Atta MG. American Society of Nephrology clinical pathological conference. Clin J Am Soc Nephrol 2014;9:818-28. [PMID: 24651072 DOI: 10.2215/CJN.12481213] [Reference Citation Analysis]
19 Abou-El-Hassan H, Zaraket H. Viral-derived complement inhibitors: current status and potential role in immunomodulation. Exp Biol Med (Maywood) 2017;242:397-410. [PMID: 27798122 DOI: 10.1177/1535370216675772] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Wei CC, Wang W, Smoyer WE, Licht C. Trends in pediatric primary membranoproliferative glomerulonephritis costs and complications. Pediatr Nephrol 2012;27:2243-50. [PMID: 22802081 DOI: 10.1007/s00467-012-2249-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]